tbuckley/cabot-search huggingface dataset:
Heberden's Nodes and Knee Osteoarthritis–Related Osseous Structural Damage: Exploratory Study From the Osteoarthritis Initiative
Authors: Arya Haj‐Mirzaian, Bahram Mohajer, Ali Guermazi, Delaram Shakoor, Ida K. Haugen, Frank W. Roemer, Shadpour Demehri
Journal: Arthritis & Rheumatology (2019)

To explore whether Heberden's nodes (HNs) could predict magnetic resonance imaging (MRI)-based knee osteoarthritis (OA)-related osseous structural progression.Five hundred seventy-five subjects from the Foundation for the National Institutes of Health project underwent clinical examination to evaluate HNs at baseline and knee MRI at baseline and 24 months. The MRI was read according to the semiquantitative MRI OA Knee Score and quantitative periarticular bone morphology measures. Adjusted linear/logistic regression models were implemented to assess the association between the presence of HNs at baseline examination and worsening of MRI-defined osseous structural damage, and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated.Comparing patients with HNs (n = 395) and patients without HNs (n = 180), more periarticular bone area expansion in the knee joint was seen in the patients with HNs over 24 months (adjusted OR [ORadj ] 1.39 [95% CI 1.06, 1.83], corrected P [Pcorr ] = 0.019), especially in the medial femur (ORadj 1.49 [95% CI 1.05, 2.13], Pcorr = 0.026) and lateral femur (ORadj 2.51 [95% CI 1.58, 3.97], Pcorr < 0.001), femoral notch (ORadj 1.37 [95% CI 1.02, 1.84], Pcorr = 0.04), and lateral trochlea (ORadj 1.44 [95% CI 1.08, 1.9], Pcorr = 0.012). However, a trend toward less osteophyte worsening was seen in patients with HNs in the whole knee joint (ORadj 0.63 [95% CI 0.40, 1.02], Pcorr = 0.058), particularly in the femur region (ORadj 0.54 [95% CI 0.31, 0.95], Pcorr = 0.03), compared to patients without HNs.The presence of HNs was associated with increased MRI-based periarticular bone area expansion, but less osteophyte worsening over 24 months in the knee joint, especially in the femoral region.
Abstract 84: The Circulating MicroRNA Study for Children with Acute stage of Kawasaki disease
Authors: Sheng L Jan, Chi R Tsai, Sheng C Chan, Yun C Fu, Ming C Lin
Journal: Circulation (2015)

Background: Kawasaki disease (KD) is a systemic vasculitis syndrome related to immune dysregulation. MicroRNAs (miRNAs) can regulate the expression of protein-coding genes, and have been used as a biomarker for the diagnosis of various diseases. This study was designed to identify plasma miRNAs changed in patients with acute stage of KD and to identify candidate miRNAs. Methods: A total of ten children, ranged from 9 months to 5 years old, with acute stage of KD were enrolled. The profiles of plasma miRNAs were analyzed by miRNA arrays. The miRNAs of interest identified by array were confirmed by reverse transcription-quantitative PCR (qRT-PCR). Results: In comparison with the convalescent stage, plasma miR-10a (ten of ten) and miR-155 (eight of ten) were significantly down-regulated during the acute stage of KD. Pathway analysis of the combinatorial effects of these two microRNAs (DIANA miRPath) indicated the genes involved in the T-cell receptor signaling pathway (p.= 2.604015e-05), the MAPK signaling pathway (p.=4.541392e-05) and the Toll-like receptor signaling pathway (p.= 0.0001528698) that were highly co-regulated by these two miRNAs. Conclusions: This is the first report of uncovering circulating miRNAs involved in patients with acute stage of KD. The results of this study indicated that the miRNAs might play a crucial role in the immune dysregulation of acute KD. Further studies and more KD patients should be investigated to elucidate the roles and as biomarkers of these miRNAs for early diagnosis of acute KD. Keywords: Biomarker, Children, Kawasaki Disease, MicroRNAs
Abstract 4: Analysis of West Coast Atmospheric Circulation Patterns and Kawasaki Disease “Dry Spells”
Authors: Jane C Burns, Mary Tyree, Erika K Berry, Xavier Rodó, Daniel R Cayan, Shaun S Berger, Margaret Bruce, Jennifer Daru, Jennifer L Everhart, Michael J Gilbert, Judith Guzman-Cottrill, Heather Hindo, Jessica S Kosut, Gregory H Kurio, Nathan C Lee, Chad Y Mao, Marian E Melish, David E Michalik, Sameer Pathare, Michael Portman, Heather Schultz, Margaret Trost, Stephanie A Yee-Guardino
Journal: Circulation (2015)

Background: Tropospheric winds from northeastern China have been linked to fluctuations in Kawasaki disease (KD) cases in Japan. These winds may carry aerosols that trigger KD in genetically susceptible children. We investigated whether reduced numbers of KD cases were linked to large scale circulation patterns affecting the U.S. West Coast. Methods: KD cases with either date of onset of fever or date of hospitalization (PHIS, Pediatric Health Information System) were obtained from 5 sites from Seattle to San Diego from 1995-2014. Six days were subtracted from date of hospitalization to approximate date of onset. For each site, periods from December-March were identified for which there were no KD cases for an interval of ≥10 days, called “KD dry spells”. Daily NCEP-NCAR atmospheric Reanalysis 700hPa height anomalies were used to represent the atmospheric circulation. Results: From 27-48 dry spells were defined for each site. Composites of atmospheric circulation from Day -20 to Day +10 relative to first day of a dry spell were created for each study site. The atmospheric circulation preceding the KD dry spell featured a higher than normal pressure center (results in weakened onshore flow) either offshore over the North Pacific or directly over the site. The circulation anomalies were statistically significant, and unlikely to have occurred by chance. The dry spell pattern intensified and persisted over several days. The strongest anomalous atmospheric circulation (and associated blocked wind flow) occurred between Day -6 to -1 relative to the start of the dry spell. A similar pattern was shared by 4 of the 5 sites. One site featured strong high pressure anomalies &gt; 6 days before the KD dry spells, but only a weak anomaly in the Day -6 to-1 interval preceding the dry spell. Conclusion: This analysis reinforces results from previous studies of KD case fluctuations in Japan wherein anomalous KD activity was associated with particular wind flow patterns. The circulation patterns associated with the West Coast KD “dry spells” suggest that reduced wind flow from the North Pacific results in reduced KD occurrences. These results support the hypothesis that a KD agent is transported by winds, possibly from a shared source region with transport of the agent across the Pacific.
SAT0549 Autologous hematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) – a ebmt retrospective survey
Authors: T. Alexander, C. Samuelson, T. Daikeler, J. Henes, L. Skagerlind, M. Akil, G. Ehninger, E. Jantunen, D. Farge, J. Snowden
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> ANCA-associated vasculitides (AAV) are chronic autoimmune diseases, which can present with life-threatening multi-system involvement. Despite the use of rituximab and other available modern biologic therapies some patients with AAV develop severe and refractory courses of disease. <h3>Objectives</h3> The aim of this study was to analyse outcomes of autologous hematopoietic stem cell transplantation (HSCT) for refractory AAV <h3>Methods</h3> Adults receiving HSCT for AAV and whose data were registered within the EBMT Autoimmune Disease Working Party (ADWP) were identified retrospectively through the EBMT database. Treating physicians were surveyed to produce a retrospective evaluation of outcomes. <h3>Results</h3> 7 patients underwent HSCT primarily for AAV between 1999–2014 in 6 centres across Europe. 5 females and 2 males were transplanted; 6 had a diagnosis of granulomatosis with polyangiitis (GPA) and 1 eosoniphilic granulomatosis with polyangiitis (EGPA). Median age was 39 years (range 32–55 years). Patients had received 4–6 prior lines of therapy, including cyclophosphamide (CYC, with median cumulative dose of 80 g) and steroids in every case, and rituximab in 4 cases. Stem cell source was peripheral blood in every case; CD34-selection was performed in 4 cases, mean CD34<sup>+</sup> cell dose was 4.2 × 10<sup>6</sup>/kg (range 0.6–7.9 × 10<sup>6</sup>/kg). Conditioning regimen was CYC/ATG in 5 patients and CYC in 2 patients. Median follow-up was 86 months (range 1–204 months). Transplant-related mortality (TRM) occurred in 2 causes. All but one patient went into remission but 3 later relapsed at 6, 12 and 36 months, respectively, and required further treatment for disease control. At time of last clinical follow-up, 3 patients had drug-dependent partial response; 1 had drug-dependent complete remission and 1 had drug-free complete remission. <h3>Conclusions</h3> Outcomes of HSCT for these heavily pre-treated AAV patients were variable. Only 1 patient achieved drug-free complete remission and TRM was observed in a quarter. Nevertheless, HSCT had the potential to stabilise AAV in patients who initially failed to respond to conventional therapies. These data do not support HSCT for advanced stage ANCA-positive vasculitis, although it may have a place as salvage treatment in otherwise refractory patients. As for other autoimmune diseases, HSCT may provide better outcomes when performed at early stage of disease. Overall, HSCT should only performed in clinical trial settings in experienced centres. <h3>Disclosure of Interest</h3> None declared
Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use
Authors: Mengzhen Liu, Yu Jiang, Robbee Wedow, Yue Li, David M. Brazel, Fang Chen, Gargi Datta, Jose Davila-Velderrain, Daniel McGuire, Chao Tian, Xiaowei Zhan, Hélène Choquet, Anna R. Docherty, Jessica D. Faul, Johanna R. Foerster, Lars G. Fritsche, Maiken Elvestad Gabrielsen, Scott D. Gordon, Jeffrey Haessler, Jouke-Jan Hottenga, Hongyan Huang, Seon-Kyeong Jang, Philip R. Jansen, Yueh Ling, Reedik Mägi, Nana Matoba, George McMahon, Antonella Mulas, Valeria Orrù, Teemu Palviainen, Anita Pandit, Gunnar W. Reginsson, Anne Heidi Skogholt, Jennifer A. Smith, Amy E. Taylor, Constance Turman, Gonneke Willemsen, Hannah Young, Kendra A. Young, Gregory J. M. Zajac, Wei Zhao, Wei Zhou, Gyda Bjornsdottir, Jason D. Boardman, Michael Boehnke, Dorret I. Boomsma, Chu Chen, Francesco Cucca, Gareth E. Davies, Charles B. Eaton, Marissa A. Ehringer, Tõnu Esko, Edoardo Fiorillo, Nathan A. Gillespie, Daniel F. Gudbjartsson, Toomas Haller, Kathleen Mullan Harris, Andrew C. Heath, John K. Hewitt, Ian B. Hickie, John E. Hokanson, Christian J. Hopfer, David J. Hunter, William G. Iacono, Eric O. Johnson, Yoichiro Kamatani, Sharon L. R. Kardia, Matthew C. Keller, Manolis Kellis, Charles Kooperberg, Peter Kraft, Kenneth S. Krauter, Markku Laakso, Penelope A. Lind, Anu Loukola, Sharon M. Lutz, Pamela A. F. Madden, Nicholas G. Martin, Matt McGue, Matthew B. McQueen, Sarah E. Medland, Andres Metspalu, Karen L. Mohlke, Jonas B. Nielsen, Yukinori Okada, Ulrike Peters, Tinca J. C. Polderman, Danielle Posthuma, Alexander P. Reiner, John P. Rice, Eric Rimm, Richard J. Rose, Valgerdur Runarsdottir, Michael C. Stallings, Alena Stančáková, Hreinn Stefansson, Khanh K. Thai, Hilary A. Tindle, Thorarinn Tyrfingsson, Tamara L. Wall, David R. Weir, Constance Weisner, John B. Whitfield, Bendik Slagsvold Winsvold, Jie Yin, Luisa Zuccolo, Laura J. Bierut, Kristian Hveem, James J. Lee, Marcus R. Munafò, Nancy L. Saccone, Cristen J. Willer, Marilyn C. Cornelis, Sean P. David, David A. Hinds, Eric Jorgenson, Jaakko Kaprio, Jerry A. Stitzel, Kari Stefansson, Thorgeir E. Thorgeirsson, Gonçalo Abecasis, Dajiang J. Liu, Scott Vrieze
Journal: Nature Genetics (2019)
Rapid antiretroviral therapy initiation in low- and middle-income countries: A resource-based approach
Authors: Mark W. Tenforde, A. Sarah Walker, Diana M. Gibb, Yukari C. Manabe
Journal: PLoS Medicine (2019)

Major progress has been made, but late entry to care remains common in the HIV "treat all" eraAntiretroviral therapy (ART) has substantially decreased HIV morbidity and mortality in high-income as well as low-and middle-income countries (LMICs).Several randomized trials have demonstrated benefits from starting ART regardless of CD4 count (Table 1) [1-3]; the World Health Organization (WHO) adopted a "treat all" strategy in 2015.Significant attention has been focused on rapidly initiating ART, reflected in the 2017 WHO guidelines, which recommend that ART be initiated within 7 days of HIV diagnosis and on the same day whenever possible [4][5][6].Although considerable progress has been made, a significant proportion of patients starting ART in LMICs continue to present with severe immunosuppression, with recent laboratory-based surveillance showing that one-third of South African patients still enter care with advanced HIV infection (CD4 < 200 cells/μL) [7,8].These late presenters have the highest risk for death, unmasking of opportunistic infections (OIs), and immune reconstitution inflammatory syndrome.The guidelines highlight these patients and state that "people with advanced HIV disease should be given priority for clinical assessment and treatment initiation" [6].Paradoxically, difficulties in implementing guidance on screening for OIs may result in the greatest delays in ART initiation in this population who are at the most risk. Current strategies are inadequate for identifying and preventing OIs and related deaths in late presentersIn the "treat all" era, the challenge is targeting effective prophylaxis against the bacterial, mycobacterial, and fungal pathogens that are the major causes of death in these late presenters.Such prophylaxis saves lives (see below) but also costs money and raises the potential risk of antimicrobial resistance if used indiscriminately.Further, when prophylaxis is provided conditional on a diagnostic test result, unless truly point-of-care, there is the potential for delays in ART initiation, which may substantially increase mortality risk.Specific tests that have evidence supporting their use in reducing mortality and are recommended to target treatment/prophylaxis to patients with HIV and low CD4 cell counts include tuberculosis (TB) smear, Xpert MTB/RIF and urinary lipoarabinomannan (LAM) for TB, and
Donor Lymphocyte Infusion for Primary Cutaneous T Cell Lymphomas: A Study from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the French Study Group on Cutaneous Lymphomas (GFLEC)
Authors: Sarah Faiz, Henry Abi Rached, Edouard Forcade, Noel Milpied, Marie Beylot-Barry, Ibrahim Yakoub-Agha, Nathalie Fegueux, Olivier Dereure, Patrice Chevallier, Anne Huynh, Marie Thérèse Rubio, Amandine Charbonnier, Remy Dulery, Felipe Suarez, Angela Granata, Jacques-Olivier Bay, Martine Bagot, Regis Peffault De Latour, Adèle De Masson, Olivier Carpentier, Laurent Mortier, Leonardo Magro
Journal: Blood (2018)
Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia
Authors: Evan Field, Paolo F Caimi, Brenda Cooper, Jane Little, Ehsan Malek, Leland Metheny, Marcos de Lima, Pingfu Fu, Ben Tomlinson
Journal: Blood (2018)
FRI0112 Persistence on tumour necrosis factor inhibitor (TNFI) monotherapy after achieving remission or low disease activity (LDA) on combination therapy among patients with rheumatoid arthritis (RA)
Authors: D.A. Pappas, H.J. Litman, T. Lesperance, S. Rebello, E. Karis, G. Kricorian, W. Hua, N. Accortt
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Combination therapy with TNFis and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) is standard for moderate to severe RA. <h3>Objectives</h3> To estimate persistence with etanercept (ETN) or other TNFi monotherapy among RA patients who achieved remission/LDA on combination TNFi +csDMARD therapy and then discontinued the csDMARD. <h3>Methods</h3> Data from RA patients in the Corrona registry during 10/1/2001–8/31/2017 were analysed. All patients had to be treated with TNFi +csDMARD combination therapy and to have reached Clinical Disease Activity Index remission/LDA and then discontinue the csDMARD (index date). ETN (fusion protein comprising TNF receptor and human IgG1 Fc) and other TNFi therapies (monoclonal antibodies: adalimumab, certolizumab pegol, golimumab, and infliximab) were analysed separately. Outcomes were percentages of patients persistent on index TNFi monotherapy, discontinued index TNFi, switched (to another biologic or to csDMARD monotherapy), or added csDMARD therapy (to receive combination therapy) at 6 months (primary analysis) and 12 months post-index. <h3>Results</h3> Data from 617 patients were analysed (182 ETN, 435 other TNFi); mean age (standard deviation [SD]) was 57.4 (13.3) years, 73% were female. Mean time (SD) in remission/LDA before csDMARD discontinuation was 17.0 (24.3) months. Rates of monotherapy persistence at 6 months were 56% for ETN and 45% for other TNFi (table 1). Patients with ≥6 month persistence on monotherapy had mean duration (SD) of 28.2 (22.1) months on ETN monotherapy or 27.8 (23.3) months on other TNFi monotherapy. Rates of persistence for all patients at 12 months were 46% for ETN and 33% for other TNFi. Patients with ≥12 month persistence had mean duration (SD) of 35.9 (22.6) months on ETN monotherapy or 39.3 (24.4) months on other TNFi monotherapy. For a subset of patients with &lt;6 months in remission/LDA before index date (44% of patients), rates of monotherapy persistence at 6 months were 60% for ETN and 42% for other TNFi. <h3>Conclusions</h3> Monotherapy with ETN or other TNFi is an option for patients in remission/LDA;&gt;50% of patients on ETN remained on monotherapy 6 months after discontinuing their csDMARD. <h3>Acknowledgements</h3> This study was sponsored by Corrona, LLC and the analysis was funded by Amgen Inc. <h3>Disclosure of Interest</h3> D. Pappas Employee of: Corrona, LLC, H. Litman Employee of: Corrona, LLC, T. Lesperance Consultant for: Amgen Inc., S. Rebello Employee of: Corrona, LLC, E. Karis Shareholder of: Amgen Inc., Employee of: Amgen Inc., G. Kricorian Shareholder of: Amgen Inc., Employee of: Amgen Inc., W. Hua Employee of: Corrona, LLC, N. Accortt: None declared
FRI0526 The impact of disease characteristics in knee and hip osteoarthritis on recommendations for joint replacement
Authors: J. Callhoff, A. Postler, K. Albrecht, A. Zink, K.-P. Günther
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Joint replacement in osteoarthritis (OA) is a major reason for hospitalisation in Germany.<sup>1</sup> <h3>Objectives</h3> Which factors are associated with recommendations for joint replacement in patients with symptomatic hip and/or knee OA? <h3>Methods</h3> A total of 9734 persons, insured in a large statutory health insurance in Germany (Barmer), who had a diagnosis of OA (ICD-10 codes M15 [polyarthrosis], M16 [coxarthrosis] or M17 [gonarthrosis]) in at least two quarters in 2014 were randomly selected, stratified by age, sex and diagnosis (M15/M16/M17). They were contacted by mail and asked to complete a questionnaire regarding sociodemographics, health behaviour, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, 0: no impairment- 100: extreme pain/stiffness/difficulty) and whether they had ever discussed total joint replacement (TJR) surgery with a physician. Patient-reported outcomes of the responders (n=3,564) were linked to claims data on prescriptions of pain medication and physical therapy. Persons with a diagnosis of M15 (n=1,212) were excluded from the present analysis. Patients who reported pain in the corresponding joints were analysed in three groups: OA of the knee, of the hip or of both. Logistic regression models were used to assess which parameters (age, sex, BMI &gt;30, prescription of opioids or physical therapy, WOMAC, whether the OA was mainly treated by an orthopaedist) were associated with having discussed a TJR. <h3>Results</h3> Of 2352 persons with knee or hip OA, 932 had symptomatic OA of the knee, 478 of the hip, 94 of both, and 848 did not report pain in the relevant joint(s). Mean age was 64 to 67 years, 63% to 68% were female and mean BMI was high, especially in patients with knee OA (29 kg/m<sup>2</sup>). 54%–74% had considerable impairment (WOMAC&gt;39). 72%–83% had any pain medication, 12%–25% opioids and 33%–46% physical therapy. 63%–72% were treated by orthopaedists and 45%–50% had discussed TJR. In knee as well as hip and knee OA male sex and an orthopaedist as main treating physician was associated with having discussed a TJR (table 1). Age, WOMAC and opioid prescription was only associated with a higher OR of discussing a TJR in knee OA. <h3>Conclusions</h3> Disease burden is highest in persons with concomitant knee and hip OA. Men are more likely to discuss TJR with their physician, but not in hip OA. Disease burden and treatment recommendations were only weakly associated. Therefore, other factors may be more important when considering surgery in knee and hip OA. <h3>Reference</h3> [1] Destatis W. Statistisches Bundesamt Gesundheit. Diagnosedaten der Patienten und Patientinnen in Krankenhäusern (einschl. Sterbe- und Stundenfälle). Fachserie 12Reihe6.2.1 – 2016. <h3>Acknowledgements</h3> This study was funded by the German Federal Ministry of Education and Research (01EC1405). <h3>Disclosure of Interest</h3> None declared
Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial
Authors: Delphine Rea, Fabian Lang, Dong-Wook Kim, Jorge E. Cortes, Timothy P. Hughes, Hironobu Minami, Massimo Breccia, Daniel J. Deangelo, Andreas Hochhaus, Moshe Talpaz, Yeow Tee Goh, Philipp le Coutre, Michael W. Deininger, Gabriel Etienne, Manu Sondhi, Kaushal Mishra, Paola Aimone, Janet Ng-Sikorski, Michael J. Mauro
Journal: Blood (2018)
Effects of non-health-targeted policies on migrant health: a systematic review and meta-analysis
Authors: Sol Pía Juárez, Helena Honkaniemi, Andrea C Dunlavy, Robert W Aldridge, Mauricio L Barreto, Srinivasa Vittal Katikireddi, Mikael Rostila
Journal: The Lancet Global Health (2019)

Government policies can strongly influence migrants' health. Using a Health in All Policies approach, we systematically reviewed evidence on the impact of public policies outside of the health-care system on migrant health.